This result on the safe and feasible approach for combined LSD1 inhibition along with standard chemotherapy in the clinical setting with observed induced phenotypic change from an aggressive mesenchymal CTC to less-metastatic epithelial phenotype strongly suggests the importance of LSD1 inhibition in preventing metastasis and prolonging breast cancer patient survival as a therapeutic target. Here, KDM1A is linked to breast carcinoma.